Saima Chohan1, Michael A Becker. 1. Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois, USA.
Abstract
PURPOSE OF REVIEW: To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development. RECENT FINDINGS: Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase. SUMMARY: There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.
PURPOSE OF REVIEW: To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development. RECENT FINDINGS: Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase. SUMMARY: There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.
Authors: Jason R Cantor; Tae Hyeon Yoo; Aakanksha Dixit; Brent L Iverson; Thomas G Forsthuber; George Georgiou Journal: Proc Natl Acad Sci U S A Date: 2011-01-05 Impact factor: 11.205
Authors: Qiuying Chen; Hyeong-Cheon Park; Michael S Goligorsky; Praveen Chander; Steven M Fischer; Steven S Gross Journal: PLoS One Date: 2012-06-18 Impact factor: 3.240